Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Novartis inks $3.2B subcutaneous drug delivery deal with Alteogen

Novartis inks $3.2B subcutaneous drug delivery deal with Alteogen

September 2, 2026Posted inBiotechnology

Novartis has struck a deal worth up to $3.2 billion to work with Alteogen on subcutaneous drug delivery, joining Biogen and GSK on the list of drugmakers to pay to access the technology this year.

Post navigation

Previous Post
single-cell-striatum-atlas-reveals-neurological-disorder-vulnerabilities Single-Cell Striatum Atlas Reveals Neurological Disorder Vulnerabilities
Next Post
TScan axes 75% of workforce to make room for solid tumor programs

Recent Posts

  • Tislelizumab Combined With Chemotherapy Extends Long-Term Survival in Advanced Esophageal Cancer
  • Global Survey Reveals Marked Variation in Anticoagulation Practices During Adult ECPR
  • Mutant p53 Reprograms AP-1 Complexes to Drive Cancer Cell Migration
  • Automated Telephone Cognitive Tests Track Regional Brain Atrophy Across Alzheimer Continuum
  • Circulating Vesicle Proteins Interfere With CLDN18.2 Cell and Antibody Therapies

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • September 2024
  • August 2024
  • March 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top